Kazuhiro Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuhiro Sato has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Akira Iwashima
Nagaoka Chuo General Hospital
1 shared publication- Akira Yokoyama
Department of Medical Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication - Chris Compton
Global Medical, GSK, London, UK
1 shared publication - Eiji Abe
Department of Materials Science and Engineering, The University of Tokyo, Tokyo, Japan
1 shared publication Fumio Ishizaki
Department of Urology, Nagaoka Red Cross Hospital, Niigata, Japan
1 shared publication- Hirohisa Yoshizawa
Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata City, Niigata, Japan
1 shared publication
Latest Publications
- Open Access
- 1 May 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 1477-1492
Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study
Background: In Western studies, lung microbiome changes are reported in patients with chronic obstructive pulmonary disease (COPD) and are associated with poorer outcomes, but similar studies in Asian patients or those with less severe COPD are limited. Methods: The Acute Exacerbation and Respiratory InfectionS in COPD Japan (AERIS-J; jRCT1080224632/NCT03957577) was a prospective, non-interventional study to evaluate sputum microbiome diversity at baseline and after 12 months (V2; exploratory analysis), in patients aged 40– 80 years with stable COPD (June 2019–June 2022). Baseline sputum potentially pathogenic organisms (PPOs) were identified. Blood cell counts and COPD Assessment Test (CAT) scores were collected at baseline and COPD symptoms measured over 12 months using the Evaluating Respiratory Symptoms in COPD and EXAcerbations of Chronic pulmonary disease Tool, collected by eDiary. Results: Patients (N=63) had a mean age of 72.8 years, and percent predicted post-bronchodilator forced expiratory volume in 1 second was 58.3%; 92% were male. Across 62 baseline sputum samples, microbiome composition was similar between 16S rRNA/metagenomic datasets. Patients graded Global Initiative for Chronic Obstructive Lung Disease (GOLD) III versus GOLD I/II had minimal differences in their microbial taxonomic profile and no differences in microbial diversity (Wilcoxon P=0.71). Alpha diversity (Shannon index) positively correlated with blood basophils (rho=0.41; P=0.0019) and negatively correlated with CAT score (rho=0.36; P=0.0069). Alpha diversity and sputum (rho: − 0.0637; P=0.7836) or blood (rho: 0.1739; P=0.2043) eosinophils were not correlated. No difference in alpha (P=0.5) or beta (P=0.3) diversity or Operational Taxonomic Unit (Anosim R=− 0.024; P=0.892) was observed between PPO-positive or -negative sputum. Conclusion: A less diverse microbiome correlated with poorer health status and lower blood basophils in patients with COPD and moderate airflow limitation. There was no relationship between PPO presence and microbiome diversity. Plain Language Summary: Chronic obstructive pulmonary disease (COPD) is a progressive lung condition resulting in breathing difficulties. Research has shown that patients with COPD experience changes in the diversity of bacteria in their lungs, leading to a worsening of symptoms. The lung microbiome includes different types of bacteria, and is involved in important roles, such as regulating the immune system and protecting the lung from invading pathogens. Many studies on the microbiome have been based in western countries, and there are few studies among Asian patients and populations with moderate COPD. The aim of this year-long study was to assess the diversity of the lung microbiome in Japanese patients with COPD and moderate airflow limitation, and how it affects patients’ immunity and disease severity. Patients’ sputum and blood samples were obtained at the start of the study and the different types of bacteria in the sputum and the number of immune cells in the blood were measured. Patients’ symptoms were also assessed at study start. Results showed that a less diverse lung microbiome was associated with lower levels of blood immune cells and worse COPD symptoms. These results improve our knowledge of the lung microbiome in an Asian population with COPD, providing insights into how lower bacterial diversity may worsen patient immunity and COPD severity.
- 1 May 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 1477-1492
Open AccessSputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study
Background: In Western studies, lung microbiome changes are reported in patients with chronic obstructive pulmonary disease (COPD) and are associated with poorer outcomes, but similar studies in Asian patients or those with less severe COPD are limited. Methods: The Acute Exacerbation and Respiratory InfectionS in COPD Japan (AERIS-J; jRCT1080224632/NCT03957577) was a prospective, non-interventional study to evaluate sputum microbiome diversity at baseline and after 12 months (V2; exploratory analysis), in patients aged 40– 80 years with stable COPD (June 2019–June 2022). Baseline sputum potentially pathogenic organisms (PPOs) were identified. Blood cell counts and COPD Assessment Test (CAT) scores were collected at baseline and COPD symptoms measured over 12 months using the Evaluating Respiratory Symptoms in COPD and EXAcerbations of Chronic pulmonary disease Tool, collected by eDiary. Results: Patients (N=63) had a mean age of 72.8 years, and percent predicted post-bronchodilator forced expiratory volume in 1 second was 58.3%; 92% were male. Across 62 baseline sputum samples, microbiome composition was similar between 16S rRNA/metagenomic datasets. Patients graded Global Initiative for Chronic Obstructive Lung Disease (GOLD) III versus GOLD I/II had minimal differences in their microbial taxonomic profile and no differences in microbial diversity (Wilcoxon P=0.71). Alpha diversity (Shannon index) positively correlated with blood basophils (rho=0.41; P=0.0019) and negatively correlated with CAT score (rho=0.36; P=0.0069). Alpha diversity and sputum (rho: − 0.0637; P=0.7836) or blood (rho: 0.1739; P=0.2043) eosinophils were not correlated. No difference in alpha (P=0.5) or beta (P=0.3) diversity or Operational Taxonomic Unit (Anosim R=− 0.024; P=0.892) was observed between PPO-positive or -negative sputum. Conclusion: A less diverse microbiome correlated with poorer health status and lower blood basophils in patients with COPD and moderate airflow limitation. There was no relationship between PPO presence and microbiome diversity. Plain Language Summary: Chronic obstructive pulmonary disease (COPD) is a progressive lung condition resulting in breathing difficulties. Research has shown that patients with COPD experience changes in the diversity of bacteria in their lungs, leading to a worsening of symptoms. The lung microbiome includes different types of bacteria, and is involved in important roles, such as regulating the immune system and protecting the lung from invading pathogens. Many studies on the microbiome have been based in western countries, and there are few studies among Asian patients and populations with moderate COPD. The aim of this year-long study was to assess the diversity of the lung microbiome in Japanese patients with COPD and moderate airflow limitation, and how it affects patients’ immunity and disease severity. Patients’ sputum and blood samples were obtained at the start of the study and the different types of bacteria in the sputum and the number of immune cells in the blood were measured. Patients’ symptoms were also assessed at study start. Results showed that a less diverse lung microbiome was associated with lower levels of blood immune cells and worse COPD symptoms. These results improve our knowledge of the lung microbiome in an Asian population with COPD, providing insights into how lower bacterial diversity may worsen patient immunity and COPD severity.
- Open Access
- 18 December 2016
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 20, 77-81
Lung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1.
- 18 December 2016
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 20, 77-81
Open AccessLung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1.
- 13 October 2016
- Published by Springer Nature
- p. 93-101
Skin Sensitization Model Based on Only Animal Data by Qualitative Structure-Toxicity Relationships (QSTR) Approach
- 13 October 2016
- Published by Springer Nature
- p. 93-101
Skin Sensitization Model Based on Only Animal Data by Qualitative Structure-Toxicity Relationships (QSTR) Approach
- 5 May 2013
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 21 (9) , 2575-2581
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) are some of the most problematic symptoms for cancer patients. Triplet therapy consisting of a 5HT3 receptor antagonist, aprepitant, and dexamethasone is a guideline-recommended antiemetic prophylaxis for highly emetogenic chemotherapy (HEC). The efficacy and safety of triplet therapy using a 0.75-mg dose of palonosetron have not yet been investigated. We performed a prospective phase II study using triplet antiemetic therapy with 0.75 mg of palonosetron.
- 5 May 2013
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 21 (9) , 2575-2581
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) are some of the most problematic symptoms for cancer patients. Triplet therapy consisting of a 5HT3 receptor antagonist, aprepitant, and dexamethasone is a guideline-recommended antiemetic prophylaxis for highly emetogenic chemotherapy (HEC). The efficacy and safety of triplet therapy using a 0.75-mg dose of palonosetron have not yet been investigated. We performed a prospective phase II study using triplet antiemetic therapy with 0.75 mg of palonosetron.
- Open Access
- 4 October 2011
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 9 (1) , 116
Surgical treatment of intracystic carcinoma of the breast
Intracystic carcinoma of the breast is a type of breast cancer with favorable prognosis where cancer arises from the cystic wall. However, it is a relatively rare disease, and no general consensus has been reached on its definition, including pathogenesis, extramural invasion, and lymph node metastasis.
- 4 October 2011
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 9 (1) , 116
Open AccessSurgical treatment of intracystic carcinoma of the breast
Intracystic carcinoma of the breast is a type of breast cancer with favorable prognosis where cancer arises from the cystic wall. However, it is a relatively rare disease, and no general consensus has been reached on its definition, including pathogenesis, extramural invasion, and lymph node metastasis.
- Open Access
- 27 June 2000
- Published by Springer Nature in Spinal Cord
- Vol. 38 (6) , 382-385
Total en-bloc spondylectomy for correcting congenital kyphosis
Study design: A case report of congenital kyphosis corrected using a total en-bloc spondylectomy. Objectives: To report a new surgical technique for the treatment of congenital kyphosis with myelopathy. Setting: Department of Orthopedic Surgery, Akita University School of Medicine, Akita, Japan. Methods: A 16-year-old boy who showed a 61° angular kyphosis and a 32° scoliosis from T6 to T9 due to the failure of the vertebral bodies formation in T7 and T8 was treated with a total en-bloc spondylectomy. Results: The kyphosis was corrected to 26° (57.3%) and the scoliosis was corrected to 5° (84.4%) postoperatively. Three years postoperatively, no loss of correction has occurred and the patient has no complaints. Conclusions: Total en-bloc spondylectomy is one of the useful surgical procedures for correction of congenital kyphosis Type I, with a high correction rate.
- 27 June 2000
- Published by Springer Nature in Spinal Cord
- Vol. 38 (6) , 382-385
Open AccessTotal en-bloc spondylectomy for correcting congenital kyphosis
Study design: A case report of congenital kyphosis corrected using a total en-bloc spondylectomy. Objectives: To report a new surgical technique for the treatment of congenital kyphosis with myelopathy. Setting: Department of Orthopedic Surgery, Akita University School of Medicine, Akita, Japan. Methods: A 16-year-old boy who showed a 61° angular kyphosis and a 32° scoliosis from T6 to T9 due to the failure of the vertebral bodies formation in T7 and T8 was treated with a total en-bloc spondylectomy. Results: The kyphosis was corrected to 26° (57.3%) and the scoliosis was corrected to 5° (84.4%) postoperatively. Three years postoperatively, no loss of correction has occurred and the patient has no complaints. Conclusions: Total en-bloc spondylectomy is one of the useful surgical procedures for correction of congenital kyphosis Type I, with a high correction rate.